⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 2022Annals of the Rheumatic DiseasesOpen Access

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct02550652.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Furie et al. (2022) studied this question.

synapsesocial.com/papers/69d95032f20ef26330684777 https://doi.org/10.1136/annrheumdis-2021-220920

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Predictors of Long‐Term Renal Outcome in Lupus Nephritis Trials: Lessons Learned from the Euro‐Lupus Nephritis CohortCohort Study · 2015 · 331 citations
2Obinutuzumab for the First-Line Treatment of Follicular LymphomaOriginal Research · 2017 · 812 citations
3Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplantCohort Study · 2019 · 83 citations
4Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodiesOriginal Research · 2015 · 85 citations
5Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsOriginal Research · 2014 · 1,521 citations